Pegfilgrastim

Generic Name
Pegfilgrastim
Brand Names
Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
Drug Type
Biotech
Chemical Formula
-
CAS Number
208265-92-3
Unique Ingredient Identifier
3A58010674
Background

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...

Indication

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non­ myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...

Associated Conditions
Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
Associated Therapies
-

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

First Posted Date
2004-10-26
Last Posted Date
2018-10-17
Lead Sponsor
Amgen
Target Recruit Count
252
Registration Number
NCT00094809

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2002-05-06
Last Posted Date
2013-05-09
Lead Sponsor
Amgen
Target Recruit Count
928
Registration Number
NCT00035594

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2002-05-06
Last Posted Date
2010-02-26
Lead Sponsor
Amgen
Target Recruit Count
44
Registration Number
NCT00035620
© Copyright 2024. All Rights Reserved by MedPath